S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NASDAQ:EDIT

Editas Medicine Stock Forecast, Price & News

$65.47
-0.29 (-0.44 %)
(As of 01/25/2021 05:04 PM ET)
Add
Compare
Today's Range
$61.34
Now: $65.47
$67.66
50-Day Range
$34.49
MA: $70.25
$90.58
52-Week Range
$14.01
Now: $65.47
$99.95
Volume2.92 million shs
Average Volume3.40 million shs
Market Capitalization$4.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Editas Medicine logo

MarketRank

Overall MarketRank

1.17 out of 5 stars

Medical Sector

857th out of 1,922 stocks

Biological Products, Except Diagnostic Industry

111th out of 177 stocks

Analyst Opinion: 2.1Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000
Employees208
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.53 million
Book Value$5.12 per share

Profitability

Net Income$-133,750,000.00

Miscellaneous

Market Cap$4.10 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$65.47
-0.29 (-0.44 %)
(As of 01/25/2021 05:04 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

How has Editas Medicine's stock price been impacted by Coronavirus?

Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EDIT stock has increased by 223.0% and is now trading at $65.47.
View which stocks have been most impacted by COVID-19
.

Is Editas Medicine a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View analyst ratings for Editas Medicine
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Editas Medicine?

Wall Street analysts have given Editas Medicine a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Editas Medicine wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Editas Medicine
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) posted its earnings results on Thursday, November, 5th. The company reported $0.12 EPS for the quarter, beating the Zacks' consensus estimate of ($0.66) by $0.78. The company had revenue of $62.84 million for the quarter, compared to analysts' expectations of $6.36 million. Editas Medicine had a negative net margin of 99.62% and a negative trailing twelve-month return on equity of 26.74%. The firm's quarterly revenue was up 1532.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.66) EPS.
View Editas Medicine's earnings history
.

What price target have analysts set for EDIT?

8 equities research analysts have issued 12-month price targets for Editas Medicine's stock. Their forecasts range from $14.00 to $86.00. On average, they anticipate Editas Medicine's stock price to reach $50.83 in the next year. This suggests that the stock has a possible downside of 22.4%.
View analysts' price targets for Editas Medicine
or view Wall Street analyst' top-rated stocks.

Who are some of Editas Medicine's key competitors?

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the following people:
  • Ms. Cynthia L. Collins M.B.A., Pres, CEO & Director (Age 62, Pay $1.14M)
  • Dr. Charles Albright, Exec. VP & Chief Scientific Officer (Age 62, Pay $732.79k)
  • Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
  • Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 66)
  • Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member
  • Dr. David R. Liu, Co-Founder & Scientific Advisory Board Member
  • Ms. Michelle Robertson, CFO, Principal Accounting Officer, Treasurer & Assistant Sec. (Age 53)
  • Mr. Harry R. Gill III, Sr. VP of Operations (Age 59)
  • Mr. Mark J. Mullikin, Sr. Director of Fin. & Investor Relations
  • Ms. Charlene Stern, Sr. VP & Chief Legal Officer

When did Editas Medicine IPO?

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.08%), Nisa Investment Advisors LLC (0.04%), McGuire Investment Group LLC (0.02%), Strs Ohio (0.01%), Patriot Financial Group Insurance Agency LLC (0.01%) and SevenBridge Financial Group LLC (0.01%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Charles Albright, Cynthia Collins, Jessica Hopfield, Michelle Robertson and Vickesh Myer.
View institutional ownership trends for Editas Medicine
.

Which institutional investors are selling Editas Medicine stock?

EDIT stock was sold by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC, Pacer Advisors Inc., and Sowell Financial Services LLC. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, Cynthia Collins, and Michelle Robertson.
View insider buying and selling activity for Editas Medicine
or view top insider-selling stocks.

Which institutional investors are buying Editas Medicine stock?

EDIT stock was acquired by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Lehman & Derafelo Financial Resources LLC, Strs Ohio, SevenBridge Financial Group LLC, Aries Wealth Management, Nisa Investment Advisors LLC, Buckley Wealth Management LLC, and First American Bank.
View insider buying and selling activity for Editas Medicine
or or view top insider-buying stocks.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $65.47.

How big of a company is Editas Medicine?

Editas Medicine has a market capitalization of $4.10 billion and generates $20.53 million in revenue each year. The company earns $-133,750,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Editas Medicine employs 208 workers across the globe.

What is Editas Medicine's official website?

The official website for Editas Medicine is www.editasmedicine.com.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.